Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

Blood

Volumn 113, Issue 18, 2009, Pages 4414-4424

  Chan, Gordon ^a,b   Kalaitzidis, Demetrios ^b,c   Usenko, Tatiana ^a   Kutok, Jeffery L ^c   Yang, Wentian ^b,d   Mohi, M Golam ^b,e   Neel, Benjamin G ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN; STEM CELL ANTIGEN 1; STEM CELL FACTOR; CRE RECOMBINASE; INTEGRASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PTPN11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CANCER MODEL; COLONY FORMING UNIT E; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE; HEMATOPOIESIS; HISTOPATHOLOGY; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PTPN11 GENE; SPLEEN CELL; SPLENOMEGALY; ADOPTIVE TRANSFER; ANIMAL; BONE MARROW; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMING UNIT GM; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; GENE TARGETING; GRANULOCYTE; HEMATOPOIETIC STEM CELL; LETHAL GENE; METABOLISM; MONOCYTE; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; ERYTHROCYTES; ERYTHROID PRECURSOR CELLS; FEMALE; FLOW CYTOMETRY; GENE KNOCK-IN TECHNIQUES; GENES, LETHAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; GRANULOCYTES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; INTEGRASES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SPLEEN; STAT5 TRANSCRIPTION FACTOR;

EID: 63849313577     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-10-182626     Document Type: Article

References (42)

1. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008;22:1335-1342.
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308. (Pubitemid 46480970)
3. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2007;109:862-867.
4. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev. 2007;17:23-30.
5. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179-192.
6. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468. (Pubitemid 34326699)
7. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2005;6:45-68. (Pubitemid 41397075)
8. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441-450. (Pubitemid 28101108)
9. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 1998;6: 249-254. (Pubitemid 28159307)
10. Chan RJ, Leedy MB, Munugalavadla V, et al. Human somatic PTPN11 mutations induce hematopoietic- cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood. 2005;105: 3737-3742. (Pubitemid 40628224)
11. Schubbert S, Lieuw K, Rowe SL, et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood. 2005; 106:311-317. (Pubitemid 40967207)
12. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7:179-191.
13. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10:849-857. (Pubitemid 39070859)
14. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes. J Biol Chem. 2005;280:30984-30993. (Pubitemid 41291831)
15. Lakso M, Pichel JG, Gorman JR, et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A. 1996;93:5860-5865. (Pubitemid 26190768)
16. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269: 1427-1429.
17. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528-538.
18. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121. (Pubitemid 40884400)
19. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/ inactivation in the mouse. Dev Biol. 2002; 244:305-318. (Pubitemid 34450645)
20. Terszowski G, Waskow C, Conradt P, et al. Prospective isolation and global gene expression analysis of the erythrocyte colony-forming unit (CFU-E). Blood. 2005;105:1937-1945. (Pubitemid 40731775)
21. Kalaitzidis D, Neel BG. Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS ONE. 2008;3:e3776. (Pubitemid 352751518)
22. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103: 4243-4250. (Pubitemid 38685370)
23. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101:597-602. (Pubitemid 38084682)
24. Purton LE, Scadden DT. Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell. 2007;1:263-270.
25. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest. 2001;108:709-715. (Pubitemid 32906199)
26. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment- induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 2007;129:1097-1110. (Pubitemid 46908696)
27. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007;129:1081-1095. (Pubitemid 46908695)
28. Konieczna I, Horvath E, Wang H, et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest. 2008;118: 853-867.
29. Lacorazza HD, Yamada T, Liu Y, et al. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell. 2006;9:175-187. (Pubitemid 43357944)
30. Min IM, Pietramaggiori G, Kim FS, Passegue E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell. 2008;2:380-391.
31. Heinrich AC, Pelanda R, Klingmuller U. A mouse model for visualization and conditional mutations in the erythroid lineage. Blood. 2004;104:659-666. (Pubitemid 38970558)
32. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 2006;108:2041-2044. (Pubitemid 44395019)
33. Zhang J, Liu Y, Beard C, et al. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood. 2007;109:5238-5241. (Pubitemid 46890543)
34. Zhang J, Socolovsky M, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood. 2003;102:3938-3946. (Pubitemid 37486974)
35. Van Meter ME, Diaz-Flores E, Archard JA, et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood. 2007;109:3945-3952. (Pubitemid 46641747)
36. Altman AJ, Palmer CG, Baehner RL. Juvenile "chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood. 1974;43:341-350.
37. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925-929.
38. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195. (Pubitemid 30105448)
39. Kim A, Morgan K, Hasz DE, et al. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 2007;109: 1687-1691. (Pubitemid 46239603)
40. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13:321-330.
41. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13:311-320.
42. Kotecha N, Flores NJ, Irish JM, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14:335-343.